MDXXF
Pharmala Biotech Holdings Inc
Mentions (24Hr)
0.00% Today
Reddit Posts
3 promising small-cap stocks you should consider adding to your watch list
Mentions
Nice list, should also check out Pharmala Biotech (CSE:MDMA) (OTC:MDXXF) Manufacturer and drug development of GMP MDMA- Primarily for PTSD therapy, other uses being studied as well. This company is primed to explode with the recent shift in healthcare in the United States under the Trump Administration. (Pro psychedelic therapy) With Lykos (MAPS) taking a step back after the FDA decision it puts Pharmala in a unique position. They are currently the top supplier of GMP MDMA globally. They have recently just signed supply contracts with institutions such as: Johns Hopkins, Harvard, Yale, Mount Sinai, etc. The new psychedelic center at Mount Sinai is funded by the VA, who recently just announced yesterday funding of 1.5M for the first study of this in over 5 decades. The tides are starting to shift and this is just the tip of the iceberg for what could be to come. They have also just recently signed an LOI with an institution to supply their clinical trial in exchange for the full data license of the results. (Expected to be finalized prior to 2024 calendar year) The supply side is great for revenue but they are also in the works of kicking off their P2 trial for their molecule (APA-01). This is where the potential for the big money is. The FDA's large concern of MDMA therapy was the safety of using generic MDMA as there are a few side effects associated with its use. Pharmala's molecule has been proven to mitigate these side effects with the use of their own molecule which essentially is a form of MDMA that still gives the effective feeling of MDMA but eliminates the risk of side effects. Pharmala also has a JV in Australia (Legalized MDMA therapy July 2023) with Cortexa. It was a slower rollout than expected although it is ramping up as Cortexa's recent update showed an increase in patients and training for licensed practitioners. They currently have an agreement for onshore manufacturing there.
Pharmala Biotech- [MDMA.CN/MDXXF](http://MDMA.CN/MDXXF) Look out for this company to capitalize off the Psychedelic boom. Perfect storm brewing with the many potential changes coming to the United States health sector under new leadership. One of the only suppliers of GMP MDMA. Currently supplying Johns Hopkins, Harvard, Yale, Mount Sinai, etc. Could get explosive come 2025.
MDXXF, RVVTF, MSCLF, BVAXF I plan to hold most of these for the long term, along with ELTP, and ATAI
$MDXXF - Pharmala Biotech setting up for a moon launch. [https://x.com/PharmAlaBiotech/status/1857067046011273641](https://x.com/PharmAlaBiotech/status/1857067046011273641)
MDXXF (MDMA.CN) Banking psychedelics (MDMA) approval to treat mental health.
18c CAD today on CSE. Also, on OTC as MDXXF at 13.42c USD.
Dumb question… what’s with Pharmala? $MDXXF.
Place your bets! My 3 sector Picks Pharmala Biotech ($MDMA $MDXXF) Numinus $NUMI Cybin $CYBN
Which platform do you use to purchase MDXXF? Fidelity is charging me a $50 fee just to purchase
Bought MDXXF on a whim this morning and now up 16%
Any Idea how to trade MDXXF Pharmala without the $50 foreign fee?
I’ve been holding NUMI for a couple years now, however I have MDXXF on my watch list. I see it’s trading at .21 so maybe tomorrow I’ll buy me some shares💰💰
maybe youre talking about MDXXF, somebody on here said theyre changing their name that could by why/true then. but im talking about CSE:MDMA which is not frozen
Poutinepogo (?) is still long and strong with $MDMA $MDXXF Imo,in 2-3 years,there will be a frenzy for everyone wanting to try MDMA therapy to get better mentally. I'm not saying it will save the world,just that it will become a trend,and $MDMA $MDXXF, with their regulatory expertise will have -already has-a huge piece of that pie... A public company that doesn't dilute,a first-mover with a low burn rate,that is gonna help a lot of people around the world...and make me earn lots of money 🗺️🕺🚀
$MDMA / MDXXF (Pharmala Biotech). ($40k invested) Manufacturer/supplier of GMP MDMA for clinical trials and in person mdma-alternate therapy as well as drug discovery with their own novel mdxx molecule pipeline going into phase 2. Currently supplying SAP in Canada, and the TGA in Australia. Recently turned a profit (first in the psychedelic sector), low burn, small sub 100mill float, has a joint venture in Australia with Vitura for onshore manufacturing, has the fda approval for their Laneo brand in U.S. for trial use, in talks with big pharma to partner up for their own trials. Also waiting to hear about fda ruling on MDMA rescheduling in U.S. for therapeutic use. Management is well connected and has an impressive history from previous companies and has proven they can manage properly.
$MDMA/$MDXXF for sure, the chart looks beautiful and the quarter over quarter growth on revenues with such high margins is really nice to see in this space.
I'm betting on PharmaAla (MDMA:CSE) (MDXXF:OTC) Fiscally responsible management team that is actually delivering MDMA to customers worldwide. Profitable last quarter and is expected to start phase 2 clinical trial for their phase lead drug candidate ALA-002 in Q1/24 (shown better safety and efficacy over generic MDMA in preclinical studies) The goal is to partner with big pharma on the ALA-002 trial. Also Keeping an 👁️ $NUMI and $CYBN
MDXXF for USA, MDMA for Canada. Its on the US OTC exchange. Maybe contract your broker?
Where can I purchase MDXXF stock? I can't purchase it on WEBULL or SOFI ?? Should I go through my Edward's Jones advisor?
Definitely PharmAla Biotech Holdings (CSE:MDMA) (OTC:MDXXF) From their most recent news release….. "PharmAla showed a quarterly profit for the first time in its history, validating its low-overhead manufacturing business model. PharmAla believes that this is the first quarterly profit for any publicly-traded psychedelics company.” “The company is furthermore proud to confirm that the first-ever dose of MDMA issued under the Australian Authorized Prescriber Scheme was manufactured by PharmAla Biotech."
$MDMA $MDXXF 
MDXXF is the otc ticker, vs MDMA which is the Canadian (cse) ticker - it’s the same company
$MDMA $MDXXF The ceo Nick Kadish and his team refused to dilute the company. Now,talk about a CEO ! Big pharma partnership soon.
I’m seeing Pharmala as #MDXXF. Why the difference?
What’s the financials on $MDMA & $MDXXF
$MDXXF & $MMED among others stand to gain from expected FDA approval this coming week of pharmaceutical grade MDMA drug (3,4-methylenedioxymethamphetamine) (an empathogen) otherwise known on the street as Ecstacy (less potent) for treatment of certain psychiatric conditions notably PTSD. Ostensibly just 2 doses has proven very effective when coupled with psychiatric therapy. This may lead to the opening of clinics for eating disorders, PTSD, anxiety, defensiveness, and other mental ailments. The USA- FDA in 2017 classified it as " Breakthrough Therapy." Already approved in Australia. Multiple third stage clinical trials are in progress at 15 locations spanning USA, Canada and Israel.
MDXXF is going to get the short squeeze today